Sofinnova Partners’ growth deal, plus BioCentury’s Distillery on tap

Plus: Caribou’s clinical data and how biopharmas are weighing their commitment to Russian patients

The sale of a minority stake in Sofinnova Partners to PE firm Apollo will allow the European VC to grow while retaining its independence. Fresh off a conversation with Sofinnova’s Antoine Papiernik, Associate Editor Stephen Hansen explains the 50-year-old firm’s proactive approach to finding a partner among private equity firms and what’s next for the firm now that it has more financial firepower. The podcast team also discusses the latest translational tidbits from BioCentury’s Distillery, the first look at clinical data from the CRISPR-based gene editing platform of Caribou Biosciences Inc. (NASDAQ:CRBU) and how biopharma companies are weighing their commitment to Russian patients against calls to disengage from the country due to Moscow’s war on Ukraine.